Search

Repligen Corp

Fechado

SetorSaúde

132.37 -3.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

131.74

Máximo

134.28

Indicadores-chave

By Trading Economics

Rendimento

-5M

8.3M

Vendas

-3.7M

194M

P/E

Médio do Setor

159.879

62.58

EPS

0.48

Margem de lucro

4.29

Funcionários

2,000

EBITDA

-13M

32M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+25.31% upside

Dividendos

By Acuity

Próximos Ganhos

28 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.5B

8.2B

Abertura anterior

136.23

Fecho anterior

132.37

Sentimento de Notícias

By Acuity

25%

75%

51 / 340 Ranking em Healthcare

Repligen Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de jul. de 2026, 19:06 UTC

News

Repligen Corp is under scrutiny as a stock to avoid, with concerns over its $763.3 million revenue and declining operating margins. Shares are trading lower today.

22 de jul. de 2026, 19:25 UTC

News
Event
Social Media

Repligen Corp is acquiring BioLife Solutions for about $1.5 billion, offering $11.25 in cash and stock, with a projected $20 million in synergies.

21 de jul. de 2026, 22:56 UTC

Repligen Corp shares are higher in after-market trading, despite a recent trend of lower closes. Broader market sentiment may be influenced by the Nikkei 225 surge.

20 de jul. de 2026, 18:06 UTC

Repligen Corp shares are higher today, reflecting positive market sentiment despite earlier intraday fluctuations. No specific news was identified to explain the movement.

Comparação entre Pares

Variação de preço

Repligen Corp Previsão

Preço-alvo

By TipRanks

25.31% parte superior

Previsão para 12 meses

Média 165.36 USD  25.31%

Máximo 207 USD

Mínimo 142 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Repligen Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

11

Comprar

3

Manter

0

Vender

Sentimento

By Acuity

51 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat